IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4102
Positioning
Market Dominance
Services
Business Services
$196M
Matthew W. Foehr
Avista Public Acquisition Corp. II does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization or similar business combination. The company focuses on pursuing businesses in the healthcare industry.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = OABI ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$OABI OmniAb, Inc. | 35 | 28 | 28 | 40 | - | - | -24.1% | -21.6% | 99.0% | -538.4% | -494.0% | -70.6% | 0.0% | 12.0x | $196M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
OmniAb, Inc. (OABI) receives a "Avoid" rating with a composite score of 35.1/100. It ranks #4102 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Matthew W. Foehr
Chief Executive Officer
Labor Force
7
28
36
50
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for OABI
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for OABI.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 28 | 13 | +15ALPHA |
| MOMENTUM | 40 | 37 | +3NEUTRAL |
| VALUATION | 28 | 20 | +8ALPHA |
| INVESTMENT | 36 | 58 | -22DRAG |
| STABILITY | 50 | 51 | -1NEUTRAL |
| SHORT INT | 28 | 14 | +14ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -24.1% (sector 5.3%)
GM 99% vs sector 60%, OM -538% vs sector 4%
Capital turnover N/A, R&D intensity 328.9%
Rev growth -71%, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags OmniAb, Inc. with an Avoid rating, assigning a composite score of 35.1/100 and 1 out of 5 stars. Ranked #4102 of 7,333 stocks, OABI falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
OABI's quality score of 28/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -24.1% (sector avg: 5.3%), gross margins of 99.0% (sector avg: 59.6%), net margins of -494.0% (sector avg: 2.3%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
OABI registers a value score of just 28/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.88x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
OmniAb, Inc.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -70.6% vs. a sector average of 7.8% and a return on assets of -21.6% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
OABI is currently showing below-average momentum at 40/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -70.6% year-over-year, while a beta of 0.97 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 50/100, OABI exhibits average financial resilience. Key stability metrics include a beta of 0.97 and a debt-to-equity ratio of 12.00x (sector avg: 0.3x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
OmniAb, Inc.'s short interest score of 28/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 12.00x), micro-cap liquidity risk. At $196M (micro-cap), OABI carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
OmniAb, Inc. is a micro-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #4102 of 7,333 overall (44th percentile). Key comparisons include ROE of -24.1% trailing the 5.3% sector median and operating margins of -538.4% below the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While OABI currently exhibits a AVOID profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (28) would have the largest impact on the composite score.
ROE 555% BELOW SECTOR MEDIAN
Gross Margin 66% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 15440% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate OmniAb, Inc. (OABI) as Avoid with a composite score of 35.1/100 at a current price of $1.73. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (50th percentile) and momentum (40th percentile), which together account for the majority of the composite score. Offsetting weakness in value (28th percentile) and quality (28th percentile) tempers our overall conviction. We assign a No Moat rating (31/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
OmniAb, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.1/100 places it at rank #4102 in our full 7,333-stock universe. At $196M in market capitalization, OmniAb, Inc. is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -71% combined with momentum at the 40th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 99% (+39.4pp vs sector) narrow to operating margins of -538% (-541.9pp vs sector) and net margins of -494.0%, yielding a gross-to-net conversion rate of -499%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $1.73, OmniAb, Inc. is trading at a premium to fundamental value. Our value factor score of 28/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.9x, P/S of 16.9x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 99% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A conservative balance sheet (12% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 35.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -71% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -494.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to OmniAb, Inc.. Key risk factors include current negative profitability (net margin -494.0%), weak quality scores (28th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -494.0%); weak quality scores (28th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 50th percentile and quality factor at the 28th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 99% provide a buffer against cost pressures; conservative leverage (12% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate OmniAb, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-24.1%), negative profitability, weak asset returns (ROA -21.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — OmniAb, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, OmniAb, Inc. receives a Avoid rating with a composite score of 35.1/100 (rank #4102 of 7,333). Our quantitative framework assigns a No Moat (31/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 36/100.
Our analysis does not support a constructive view on OmniAb, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign OmniAb, Inc. a meaningful economic moat, scoring 31/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10.2/20.
The strongest moat sources are margin superiority (10.2/20) and financial resilience (9.1/20). GM 99% vs sector 60%, OM -538% vs sector 4%. Interest coverage N/A. These pillars form the core of OmniAb, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include growth durability (1.8/20) and economic value creation (2.6/20). Rev growth -71%, 4yr history. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect OmniAb, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 99% providing a solid profitability foundation, declining revenues (-71%) that pressure the earnings outlook. The margin cascade from 99% gross to -538% operating to -494.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 28th percentile.
The margin profile shows gross margins of 99%, operating margins of -538%, net margins of -494.0%. Return metrics include ROE of -24.1% and ROA of -21.6%. Relative to the Services sector, gross margins are 39.4 percentage points above the sector median of 60%, and ROE of -24.1% compares to a sector median of 5.3%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 12%, revenue growth of -71%. The sector median D/E is 0%, putting OmniAb, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (28th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081
EMERYVILLE, Calif., February 24, 2026--OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the Leerink Global Healthcare Conference taking place March 8-11, 2026, at the W South Beach in Miami. Management will present a corporate overview on Tuesday, March 10th at 3:40 p.m. Eastern time and will hold one-on-one meetings with investors registered for the event.
EMERYVILLE, Calif., February 19, 2026--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Key Insights Significantly high institutional ownership implies OmniAb's stock price is sensitive to their trading...
EMERYVILLE, Calif., December 15, 2025--OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry’s first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego.
Insiders who bought OmniAb, Inc. ( NASDAQ:OABI ) stock in the last 12 months were richly rewarded last week. The...